FEATURED ARTICLES
The Unexpected Challenges Of Moving From Discovery To Clinical
Keystone Nano, a small oncology-focused company in State College, PA, recently received an IND approval from the FDA and launched its first clinical trial. While that transition from discovery to clinical is an exciting time for most companies, it is also a time of greater challenges as your product is used in humans for the first time. Jeff Davidson, CEO of Keystone Nano, has learned about many of these challenges first-hand.
-
![Can We Improve On ClinicalTrials.gov]( "Can We Improve On ClinicalTrials.gov?")
Can We Improve On ClinicalTrials.gov?Today, patients and pharma professionals looking for information on clinical trials generally visit ClinicalTrials.gov. On the site, users can search by condition/disease, country, and other keywords. Patients can find studies in which to participate, and researchers are able to find information on more than 250,000 studies being conducted in the U.S. and 200 other countries. But is it time for a new database that better meets the needs of pharma executives and researchers?
-
![Become The Clinical Partner Of Choice]( "Become The Clinical Partner Of Choice")
Become The Clinical Partner Of ChoiceMany pharmaceutical companies have started to look at their processes through the lens of valued, external partners. While companies will continue to evaluate the effectiveness of their external partners, many are increasingly looking in the mirror to see at what kind of partner they are to work with.
-
![Distrust Of Trials Declining Among Minority Populations]( "Distrust Of Trials Declining Among Minority Populations")
Distrust Of Trials Declining Among Minority PopulationsDistrust of pharma companies and clinical trials has long been cited as one reason for the low enrollment numbers of minorities in clinical studies. But a new survey finds that lack of trust may be waning, while other factors continue to contribute to low participation rates.
